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Abstract
Introduction: Bronchopulmonary neuroendocrine tumours (BP NET) cause many diagnostic and therapeutic problems. There is an 
ongoing search for biochemical markers of activity of these tumours. The use of polypeptide growth factors seems potentially feasible in 
establishing the diagnosis, prognosis and treatment of these tumours.
Material and methods: We included 41 patients aged 25 to 78 years with histopathologically confirmed typical and atypical bronchopul-
monary carcinoid tumours and 20 healthy volunteers. We assessed the levels of specific and non-specific markers of these tumours and 
of selected growth factors relative to TNM classification.
Results: The levels of specific markers (serotonin and its metabolite, 5-hydroxyindoleacetic acid [5HIAA]) and non-specific markers (chro-
mogranin A [CgA]) were significantly higher in patients with atypical carcinoid tumours. The serum levels of hepatocyte growth factor 
(HGF), vascular endothelial growth factor (VEGF) and VEGF receptor-1 (VEGFR-1) were significantly higher in patients with carcinoid 
tumours versus the control group. The levels of VEGFR-1 closely correlated with TNM classification. No such correlation could, however, 
be confirmed for the levels of HGF, VEGF or VEGFR-2. 
Conclusions: Determination of CgA, serotonin and 5HIAA may be useful in the diagnosis of BP NET, particularly in atypical carcinoid 
tumours, and their levels depend on the presence of distant metastases. Determination of growth factors (VEGF and its receptor, VEGFR-1, 
and HGF) may prove useful in the clinical diagnosis of these tumours, while the assessment of VEGFR-1 expression may be helpful in 
tumour staging. (Endokrynol Pol 2012; 63 (6): 477–482)
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Streszczenie
Wstęp: Nowotwory neuroendokrynne płuc sprawiają wiele trudności diagnostycznych i leczniczych. Trwają więc poszukiwania bio-
chemicznych wskaźników aktywności tych nowotworów. Wykorzystanie polipeptydowych czynników wzrostu wydaje się potencjalnie 
możliwe w diagnostyce, rokowaniu i leczeniu.
Materiał i metody: Badaniem objęto 41 chorych w wieku 25–78 lat z potwierdzonymi histopatologicznie rakowiakami typowymi i aty-
powymi płuc oraz 20 zdrowych woluntariuszy, u których oceniono zależność stężeń specyficznych i niespecyficznych markerów tych 
nowotworów oraz wybranych czynników wzrostu w zależności od stopnia zaawansowania w skali TNM.
Wyniki: Stężenia badanych markerów specyficznych (serotonina oraz jej metabolit — kwas 5-hydroksyindolooctowy [5HIAA]) i niespe-
cyficznych (chromogranina A [CgA]) były istotnie wyższe u chorych z rakowiakiem atypowym. Stężenia czynnika wzrostu hepatocytów 
(HGF), czynnika wzrostu śródbłonka naczyniowego (VEGF) i jego receptorów R1 (VEGFR-1) było istotnie większe u chorych z rakowia-
kami w porównaniu z grupą kontrolną. Stężenia VEGFR-1 korelowały ściśle ze stopniem zaawansowania w skali TNM, czego nie udało 
się potwierdzić badając stężenia HGF oraz VEGF i VEGFR-2. 
Wnioski: Oznaczanie stężeń CgA, serotoniny i 5HIAA może być przydatne w diagnostyce rakowiaków atypowych płuc a wielkość tych 
stężeń zależy od istnienia przerzutów odległych. Potencjalną rolę oznaczeń czynników wzrostu (VEGF i jego receptorów VEGFR-1 oraz 
HGF) upatrujemy w diagnostyce klinicznej tych nowotworów, natomiast ocena ekspresji receptorów VEGFR-1 może być użyteczna 
w ocenie stopnia zaawansowania procesu nowotworowego. (Endokrynol Pol 2012; 63 (6): 477–482)
Słowa kluczowe: chromogranina A, serotonina, 5HIAA, czynniki wzrostu, VEGF, VEGFR, HGF, rakowiak typowy i atypowy płuc
Introduction
Bronchopulmonary neuroendocrine tumours (BP NET) 
are a group of neoplasms originating from endocrine 
cells disseminated throughout the human body. Neu-
roendocrine cells of the respiratory tract, also known as 
enterochromaffin cells (Kulchitsky cells), account for 0.17% 
of all the cells of the respiratory tract epithelium and are 
located in the basal layer of the bronchial epithelium and 
bronchial glands [1]. The aetiology and pathogenesis of 
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BP NET are unclear, which to possesses difficulties in 
determining their clinical course and prognosis [2–4]. 
Due to the untypical nature of this rare group of tumours, 
there is an ongoing search for biochemical markers that 
might be helpful in establishing the diagnosis and pre-
dicting progression of the disease in various stages of the 
tumour. Laboratory evaluation of these tumours involves 
the determination of specific markers (serotonin and its 
metabolite 5-hydroxyindoleacetic acid [5HIAA]) and non-
specific markers (chromogranin A [CgA]) [5]. There are 
scarce and conflicting reports on the use of polypeptide 
growth factors involved in the processes of neoplastic 
transformation, proliferation and angiogenesis as potential 
biochemical markers of activity of these tumours. Angio-
genesis is strictly related to tumour growth and metastatic 
potential of tumours. Neuroendocrine tumours have long 
been known to be highly vascular. In the past, carcinoid 
tumours were believed to be characterised by a benign 
clinical course. However, it has been proved in the past 
20 years that these are in fact malignant tumours, and the 
prognosis and treatment outcomes depend on cell type, 
differentiation and stage of the disease. Compared to 
other malignant tumours of the lung, carcinoid tumours 
tend to occur at a younger age and have a more favour-
able prognosis than other primary tumours of the lung, 
although this strictly depends on tumour type and stage. 
Studies have demonstrated that levels of such angiogenic 
factors as vascular endothelial growth factor (VEGF) [6], 
which exerts its actions through specific thyrosine kinase 
receptors (VEGFR), and hepatocyte growth factor (HGF) 
correlate with the aggressiveness of tumours in various 
organs and may be used as prognostic factors. The activ-
ity of VEGF is not limited to the vascular endothelium 
but may extend to certain other cell types (VEGF may, 
for instance, stimulate migration of monocytes or mac-
rophages). In vitro experiments have shown that VEGF 
stimulates mitosis and migration of endothelial cells and 
increases the permeability of capillaries. HGF is secreted by 
mesenchymal cells and acts as a cytokine mainly on cells 
of epithelial origin, cells of mesothelial origin and on the 
precursors of haematopoietic cells, regulating their growth, 
mobility and morphogenesis. Studies have demonstrated 
that when released from its regulatory mechanisms, HGF 
causes a fulminant invasion of tumour cells into adjacent 
tissues and is closely linked to the metastatic potential of 
various types of tumours [7]. Studies in patients with non-
small-lung carcinoma show a significant role in the growth 
of solid tumours of the lung and suggest a relationship with 
dissemination of the underlying disease [8, 9].
The aims of our study were to: assess the levels of 
specific markers (serotonin and its metabolite 5HIAA), 
non-specific markers (CgA) and selected growth factors 
(VEGF, HGF, VEGFR1, VEGFR2) in patients with typical 
and atypical carcinoid tumours of the lung;
 — assess the relationship between CgA, serotonin, 
5HIAA, VEGF, VEGFR and HGF and the TNM stage 
in these patients.
Material and methods
We enrolled 41 patients aged from 25 to 78 years (mean 
age 59.4 years) with histopathologically confirmed 
bronchopulmonary carcinoid tumours and 20 sex- and 
age-matched healthy volunteers serving as controls. 
Typical carcinoid tumours were present in 54% (22/41) 
of the patients (Group 1) and atypical ones in 46% 
(19/41) of the patients (Group 2). Women accounted for 
72.7% (16/22) and men for 27.3% (6/22) of the patients in 
Group 1. The respective percentages in Group 2 were 
42.1% (8/19) and 57.9% (11/19). Patients with co-existing 
tumours in other organs were excluded from the study. 
Levels of the selected parameters were determined in 
the serum.
All the study subjects provided informed consent 
to participate in the study. The study protocol was ap-
proved by the relevant ethics committee.
In both patient groups, the patients were classified 
according to the TNM classification published in 2009 
by Travis et al. [10] (Fig. 1, 2).
Fasting blood samples for hormone determinations 
were collected at 8.00am from an arm vein. The serum 
obtained by centrifugation was stored at –70°C until 
analysis. The levels of the non-specific neuroendocrine 
tumour marker (CgA), specific neuroendocrine tumour 
markers (serotonin, 5HIAA), selected growth factors 
(VEGF, HGF) and binding proteins (VEGFR-1, VEGFR-2) 
were determined by enzyme-linked immunosorbent 
assay (ELISA). Serum levels of CgA and serotonin and 
24-hour urine levels of 5HIAA were determined using 
the µQuant (Bio-Tek), the Serotonin ELISA (ALPCO) 
and the 5-HIAA ELISA (IBL International), respectively. 
The respective analytical sensitivities of these tests were 
as follows: 2.0 U/L (normal range: 2–18 U/L); 5 ng/mL 
(normal ranges: 80–450 ng/mL [women] and 40–400 ng/ 
/mL [men]) and 0.06 mg/L (normal range: 6–10 ng/mL). 
Serum levels of HGF, VEGF VEGFR-1 and VEGFR-2 
were determined using the Quantikine (R&D Systems) 
at the analytical sensitivities of 40 pg/mL, 5 pg/mL, 
3.5 pg/mL and 4.6 pg/mL, respectively.
The results were analysed using statistical methods. 
The analysis involved a comparison of the data in the 
study patient groups and an assessment of their corre-
lations with the pTNM stage. Linear regression curves 
were applied to the observed correlations. The differ-
ences between the specific variables in the study patient 
groups were evaluated using univariate analysis of vari-
ance. P values of   <  0.05 were considered statistically 
significant. The statistical calculations were performed 
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using MedCalc. The values calculated for quantitative 
variables were expressed as arithmetic means.
Results
In the study patient population, serum levels of CgA 
and serotonin and 24-hour urine levels of 5HIAA were 
significantly elevated (p < 0.02, p < 0.01 and p < 0.04, 
respectively) in patients with atypical bronchopulmo-
nary carcinoid tumours versus patients with typical 
carcinoid tumours and the control group (Table I).
The mean levels of CgA, serotonin and 5HIAA did 
not show any significant differences relative to the 
tumour size (T) or nodal invasion (N) but were signifi-
cantly higher in patients with distant metastases (M). 
Summary results for patients with typical and atypical 
carcinoid tumours are provided in Figures 3 to 5.
Levels of selected growth factors (VEGF, HGF) were de-
termined in the study patient groups and the control group.
Levels of VEGF (mean ± SD) in patients with BP 
NET were significantly higher than in the control 
group (359.26 ± 281.03 pg/mL v. 207.08 ± 157.84 pg/mL; 
p = 0.0115) (Fig. 6).
Levels of VEGF did not differ significantly between 
patients with typical lung carcinoid tumours and 
patients with atypical carcinoid tumours, and there 
Table I. Mean levels of non-specific markers (CgA) and specific markers (serotonin and 5HIAA) in the study patient groups 
with BP NET and the control group
Tabela I. Średnie stężenia markerów niespecyficznych (CgA) oraz specyficznych (serotoniny i 5HIAA) w grupach badanych
CgA [U/L]
(normal range:  
2–18 U/L)
Serotonin [ng/mL]
(normal range: 
80–450 ng/mL)
5HIAA [mg/24 h]
(normal range: 
2–6 mg/24 h)
Typical 
carcinoid 
tumour group
13.02 (SD 9.10)
p = 0.026
164.18 (SD 
242.00)
p = 0.014
5.75 (SD 3.48)
p = 0.048
Atypical 
carcinoid 
tumour group
1020.28 (SD 
3638.46)
p = 0.018
363.94 (SD 
333.98)
p = 0.021
50.32 (SD 
148.90)
p = 0.032
Control group 8.09 (SD 6.23) 146.31 (SD 
210.30)
4.23 (SD 2.69)
Figure 1. Percentage distribution of patients with typical 
bronchopulmonary carcinoid tumours (Group 1) according to the 
TNM classification
Rycina 1. Rozkład procentowy grupy chorych z rakowiakami 
typowymi (grupa 1) w zależności od stopnia zaawansowania 
w skali TNM
Figure 2. Percentage distribution of patients with atypical 
bronchopulmonary carcinoid tumours (Group 2) according to the 
TNM classification
Rycina 2. Rozkład procentowy grupy chorych z rakowiakami 
atypowymi (grupa 2) w zależności od stopnia zaawansowania 
w skali TNM
480
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
Selected neuroendocrine tumour markers  Aleksandra Telega et al.
were no significant differences according to the TNM 
classification.
Assessment of VEGFR expression revealed that 
patients with neuroendocrine tumours of the lung 
showed higher expression of VEGFR1 than controls 
(p = 0.002). VEGFR1 levels were higher in the group 
of the most advanced tumours according to the TNM 
classification, taking into account the tumour size, 
nodal invasion and presence of distant metastases 
(Fig. 7). No such correlations were observed for 
VEGFR2.
HGF levels (mean ± SD) were significantly higher 
in patients with carcinoid tumours than in the control 
group (1,297.60 ± 362.19 pg/mL v. 996.04 ± 365.85; 
Figure 3. CgA levels (U/L) according to the TNM classification 
in patients with carcinoid tumours of the lung
Rycina 3. Stężenia chromograniny A [U/l] w zależności od stopnia 
zaawansowania według skali TNM u chorych z rakowiakami płuc
Figure 4. Serotonin levels [ng/mL] according to the TNM 
classification in patients with carcinoid tumours of the lung
Rycina 4. Stężenia serotoniny [ng/ml] w zależności od stopnia 
zaawansowania według skali TNM u chorych z rakowiakami 
płuc
Figure 5. 5HIAA levels [mg/24 h] according to the TNM 
classification in patients with carcinoid tumours of the lung
Rycina 5. Stężenia kwasu 5HIO [mg/24 h] w zależności od stopnia 
zaawansowania według skali TNM u chorych z rakowiakami płuc
Figure 6. Levels of VEGF (pg/mL) in patients with carcinoid 
tumours of the lung and in the control group
Rycina 6. Stężenia VEGF[pg/ml] u chorych z rakowiakami płuc 
oraz w grupie kontrolnej
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p = 0.001). HGF levels were also significantly higher in 
patients with atypical versus typical carcinoid tumours 
(p = 0.046) (Fig. 8). There was no correlation between 
HGF levels and TNM stage.
Discussion
Chromogranin A and serotonin are markers used in 
the laboratory evaluation of neuroendocrine tumours, 
although, as shown in other studies and confirmed in 
ours, their levels in bronchopulmonary neuroendocrine 
tumours may be within reference ranges or be slightly 
elevated before distant metastases appear (Fig. 3 and 
4). CgA and serotonin levels were within reference 
ranges in Group 1 patients (none of whom had distant 
metastases), while patients in Group 2 had considerably 
elevated CgA levels (nearly 74% of these patients had 
distant metastases).
According to the available literature, 5HIAA levels 
are within reference ranges in patients with BP NET due 
to the lack of the enzyme aromatic amino acid decar-
boxylase, which we managed to confirm in the group 
of patients with typical bronchopulmonary carcinoid 
tumours. The high 5HIAA levels in the group of patients 
with atypical carcinoid tumours might be explained 
by the presence of metastases in the majority of these 
patients, with the metastases mostly involving the liver, 
where the enzyme necessary for serotonin metabolism 
is present (Table I). The absence of correlation between 
tumour size or nodal involvement and 5HIAA levels 
and the presence of a correlation between the presence 
of distant metastases and 5HIAA levels observed in our 
study confirms this finding (Fig. 5). These observations 
do suggest a role for these markers in the diagnosis of 
BP NET despite the many conflicting literature reports 
on their usefulness in these tumours. 
Previous studies have shown that serum levels of 
VEGF and VEGFR correlate with the aggressiveness 
of tumours of various organs and targeted therapies 
that affect angiogenesis and target VEGF, among other 
factors, raising significant hopes among biologists, on-
cologists and chemotherapeutists [11–15].
Our study showed significantly higher serum levels 
of VEGF in patients with BP NET compared to the con-
trol group, which may suggest the potential usefulness 
of VEGF in the diagnosis, and a potential use of antian-
giogenic agents in the treatment of these patients [16-
20]. We did not observe any differences in VEGF levels 
relative to the primary tumour size, presence of distant 
metastases, or the histologic type (Fig. 6) and therefore 
could not confirm their usefulness as a prognostic fac-
tor. We did, however, obtain promising results when we 
evaluated VEGFR-1 levels. We observed significantly 
higher levels in patients versus controls, a close correla-
tion between elevated levels and: primary tumour size, 
development of nodal involvement and development 
of distant metastases (Fig. 7), which — in addition to 
use in the diagnosis and treatment — seems to be an 
important prognostic factor, which obviously needs to 
be confirmed in multicentre randomised studies.
The available literature provides data on the signifi-
cance of HGF in non-neuroendocrine small-cell and non-
Figure 7. Dependence between VEGFR1 expression [pg/mL] 
and the TNM classification in patients with bronchopulmonary 
carcinoid tumours
Rycina 7. Zależność ekspresji receptorów VEGFR1 [pg/ml] 
od stopnia zaawansowania w skali TNM w nowotworach 
neuroendokrynnych płuc
Figure 8. Levels of HGF [pg/mL] in the two study patient groups 
(typical and atypical carcinoid tumours of the lung) and in the 
control group
Rycina 8. Stężenia HGF [pg/ml] w dwóch grupach badanych 
(rakowiak typowy i atypowy) oraz w grupie kontrolnej
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small-cell lung carcinomas in the diagnosis, prediction of 
disease progression and assessment of response to drug 
treatment [16–18]. Based on the results of our study, 
where HGF levels were significantly higher in BP NET 
patients than in controls, it may be concluded that the 
histological type of the tumour (typical versus atypical 
carcinoid tumour) plays a significant role, while no cor-
relation has been demonstrated between HGF levels and 
the TNM classification. It is worth noting that HGF levels 
were determined in serum rather than tissue samples, 
which might have affected the determination results in 
patients in various stages of the underlying illness.
It would be valuable to continue this study in a larger 
number of patients, as it would allow us to investigate 
the biology of tumours in greater detail, including the 
role of growth factors. This would, in turn, enable us 
to make better use of them in diagnostic evaluation.
In conclusion, our study has shown a potential 
usefulness of determining the levels of specific mark-
ers (serotonin, 5HIAA) and non-specific markers (CgA) 
in the diagnosis and in the evaluation for distant 
metastases in bronchopulmonary carcinoid tumours, 
particularly in atypical tumours. We see a potential role 
for the selected growth factors, VEGF and HGF, and of 
the VEGFR1 in the clinical diagnosis of these tumours, 
while the assessment of VEGFR-1 expression may be 
useful in tumour staging.
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